

Financial Year 2025 Final Results

& Company Update (AIM:LST)

April 2026





Simon Deacon
Chief Executive Officer

Background:


- Over 30 years' experience
- Founder
- Track record of founding and acquiring growth businesses



Jim Snooks
CFO / Company Secretary

Background:

- Solid commercial awareness
- Over 30 years in senior finance roles
- Experienced in acquisitions & disposals



Andrew Hempsall
Chief Operating Officer

Background:

- PLC and PE environments
- Over 30 years in senior ops roles
- Experienced in integrating acquisitions

AgTech (AGT)

- Awarded NTU contract worth c.£0.46m (increased post-period to c.£0.60m)
- Strengthened sensorGROW® IP position through patent grant

Contract Electronics Manufacturing (CEM)

- Focused on de-risking high customer concentration and gearing for entry into higher margin markets including defence, medical and healthcare
- 14 new clients

Passive Fire Protection (PFP)

- Increasing number of Building Safety Regulator (BSR) applications on which Injectaclad is now being specified
- c.150 buildings remediated to date using the Injectaclad system
- Recent regulatory progress underpins expectations of a significantly improved H2 2026

Post-period end highlights

- Raised £6.6m to fund 3 acquisitions
- c.£4m current Group forward orders
- c.£55m current Group quoted sales pipeline



Financial Overview | Group Revenue & Gross Profit

For Financial Years ending 30 November


Group revenue (FY25)

- Group revenue of £8.6m for FY25 (£12.0m FY24)
- Year-on-year Group revenue reduced by 28.3%
- Revenue reduction relates to largest customer in the CEM division
- CEM recovery centred on gaining defence and medical accreditations
- PFP division pipeline is awaiting BSR* approvals
- BSR* has been moved from HSE to MHCLG** at the end of January 2026


Group gross profit & margin % (FY25)

- FY25 Group gross margin of 33.8%, up from 30.3% in FY24
- Year-on-year Group gross profit decreased by 20.0%
- Strong gross margin % contribution from PFP and AGT divisions
- CEM seeking higher gross margin revenues from defence, medical and healthcare

* BSR: Building Safety Regulator
**HSE: Health and Safety Executive | MHCLG: Ministry of Housing, Communities and Local Government



	FY21	FY22	FY23	FY24	FY25
Total Group Revenue (£'000)	7,394	8,167	9,295	12,037	8,632
CEM Division Revenue (£'000)	7,361	8,039	9,085	9,513	6,307
AGT Division Revenue (£'000)	33	128	222	778	965
PFP Division Revenue (£'000)	N/A	N/A	N/A	1,778	1,378
Corporate Revenue Adj. (£'000)	N/A	N/A	(12)	(32)	(18)



	FY21	FY22	FY23	FY24	FY25
Total Group Gross Margin	22.2%	17.7%	23.4%	30.3%	33.8%
CEM Division Gross Margin	22.2%	16.7%	22.6%	24.3%	28.4%
AGT Division Gross Margin	43.3%	76.9%	54.2%	49.9%	43.0%
PFP Division Gross Margin	N/A	N/A	N/A	53.3%	51.7%

For Financial Years ending 30 November


Group EBITDA*

- Continued overhead cost control in all divisions and holding company
- Administrative expenses increased only 8.0% (FY24: £3.34m to FY25: £3.60m), despite continued inflationary pressures
- Clear strategy to continue strengthening portfolio gross margins;controlling overhead costs; and driving Group revenues, to return to EBITDA positive results for FY26

Group net profit / (loss) before tax (FY25)

- FY25 net loss increased to £0.89m (FY24 £0.03m)
- H2 2024 generated net profit for the first time: £0.30m^
- H2 2025 saw a key CEM customer bring a product to end of life

^ Unaudited
* EBITDA is not presented within the Company's financial statements but has been calculated by Company management from disclosures within those reports
Δ Reportable segments disclosure for the FY22 comparable was re-stated in FY23's financial statements, due to changes in structure following acquisitions during FY23. Disclosure for FY21 remains unadjusted in the above table



Further investment to expand capacity and facilitate continued growth

- Development Assets: Further product development investment in AGT division’s sensorGROW technology: £0.10m
- Acquisition Intangible Assets: Post-period end acquisition of RLUK Injection, owner of Injectaclad, securing the PFP division’s value chain
- Non-current Assets: Post-period end acquisition of Manchester property, and plans for further investment in property, plant and equipment to support defence and medical accreditations and post-acquisition integration of Injectaclad

Group Cash and Banking facilities

- Cash position decreased at end FY25 to £0.7m with working capital facilities fully utilised (FY24: Cash £1.2m, undrawn funds £0.7m, total £1.9m)
- Net Debt increased from £0.7m to £0.9m
- Post-period end successful £6.6m fundraise with 3 acquisitions, providing a strengthened balance sheet

£,000	30/11/21	30/11/22	30/11/23	30/11/24	30/11/25
Goodwill and Acquisition Intangible Assets	-	-	1,422	1,327	1,231
Development Assets	215	708	1,059	1,127	1,119
Non-current Assets	1,374	1,437	1,278	1,197	1,035
Current Assets (exc. Cash)	3,089	4,330	3,593	3,453	2,160
Cash	3,860	591	981	1,215	723
TOTAL Assets	8,538	7,066	8,333	8,319	6,268
Current Liabilities	(3,617)	(4,309)	(4,124)	(3,780)	(3,243)
Non-current Liabilities	(1,004)	(822)	(1,742)	(2,058)	(1,471)
TOTAL Liabilities	(4,621)	(5,131)	(5,866)	(5,838)	(4,714)
Net Assets/(Liabilities)	3,917	1,935	2,467	2,481	1,554

£,000	30/11/21	30/11/22	30/11/23	30/11/24	30/11/25
Cash	3,860	591	981	1,215	723
Working capital Bank facilities	(1,125)	(1,791)	(1,563)	(543)	(680)
Current Bank loans and leases	(443)	(439)	(318)	(501)	(346)
Non-Current Bank loans and leases	(940)	(710)	(484)	(885)	(645)
Net Cash/(Debt)	1,352	(2,349)	(1,385)	(714)	(948)

AgTech



Market opportunity £12.7bn[△]
c.£34m current quoted pipeline
Gross margin FY25 43.0%


Drivers

- Food security
- Delays in transport
- Cost of materials

Route to Market

- Agronomists
- Growers
- Resellers

Contract Electronics Manufacturing



Market opportunity £21bn*
c.£1m current quoted pipeline
Gross margin FY25 28.4%

Drivers

- Onshoring
- Import tariffs
- Cost of logistics

Route to Market

- Prime contractor supply chains
- Building long term relationships
- Turnkey solution

Passive Fire Protection



Market opportunity £50bn**
c.£20m current quoted pipeline
Gross margin FY25 51.7%

Drivers

- Legislation
- Government timescales
- 40,000 buildings in the UK alone require remediation work

Route to Market

- Fire engineers
- Architects
- Contractors / building owners

[△] AGT focused Market Opportunity - aggregation of the following 2 AGT market sizes:

Report: Allied Market Research LED Grow Lights Market Analysis 2030; (<https://www.alliedmarketresearch.com/led-grow-lights-market-A12416>): USD \$12.3 billion by 2030 converted at GBP £1 = USD \$1.35.

Report: Agricultural Sensors Market 2032; (<https://www.credenceresearch.com/report/agriculture-sensors-market>): USD \$4.8 billion by 2032 converted at GBP £1 = USD \$1.35

*Report - Horizon Grand View Research 2030 (<https://www.grandviewresearch.com/horizon/outlook/electronic-contract-manufacturing-and-design-services-market/uk>): USD \$28.2 billion by 2030 converted at GBP £1 - USD \$1.35.

**Estimators price cladding replacement at 10 times government budget (theconstructionindex.co.uk)

AgTech Division Overview

Agtech divisions core products:

- Lighting
 - Environment computers
 - sensorGROW®
- c.£450k of new orders won, one of which is a Welsh university contract
 - Engaged a new sales executive to support scaling of sensorGROW® internationally
 - Implementation of sensorGROW® through global resellers. Paid trials of sensorGROW® are already operating in the UK, Mexico, Chile, Poland and Australia

Future developments

- Eco lighting
- Development of a new environment computer with an interactive digital platform/App
- Identify key stakeholders, including agronomists and resellers to build partnerships internationally
- Continue sensorGROW® developments with a nitrous oxide (N₂O) sensor

YoY AGT Revenue
up by c.24%


30 glasshouses
refurbished in the
UK in FY25

Lighting orders
shipped to Poland
and Germany



Contract Electronics Manufacturing Division Overview

- Transitioning into more profitable Defence, Medical and Healthcare markets, with superior gross margins
- New processes implemented and accreditations awarded
- Investment in new equipment and technologies to further improve efficiency
- New factory tour launched on the website showcasing the facilities and capabilities
- Remaining 10% minority interest has been purchased, as well as property which enables us to reshape for accreditations required for target markets
- The CEM facility has increased profitability on products it manufactures for other divisions within the Group
- Business development onboarded 14 new clients



YoY CEM Revenue
down by c.34% due to
pest control customer
end of life product

YoY CEM Gross Margin
up from 24.3% FY24 to
28.4% FY25

De-risking of pest control
customer concentration
from 49.2% FY24 to 30.4%
FY25 (% of Group Revenue)

Passive Fire Protection Division Overview

- Acquisition of patent protected material provider, Injectaclad, servicing 11 installers across the UK
- Injectaclad acquisition opens potential opportunity for c.£130m of quoted pipeline (based on an assumed c.£10m average quoted pipeline per external installer and an empirical c.£20m for the PFP's own installation business)
- Increasing number of Building Safety Regulator (BSR) applications on which Injectaclad is now being specified
- New northern base for Injectaclad, establishing a distribution and training facility
- Injectaclad's gross material margins are 50%+
- c.40k buildings require remediation work, including:
 - Residential / Social housing
 - Student accommodation
 - Schools / Universities
 - Hotels
 - Public buildings
 - Commercial



50% Gross margin on
installations / materials

Residents can remain in
situ whilst remediation
work is being carried out

Substantially more cost
effective than removing
the facade

Passive Fire Protection Division Overview (cont'd)

- Driven by Fire Safety Act 2021 & Building Safety Act 2022
- Government-led pledge for £6bn industry contribution to assist with national remediation works. £1.1bn of this pledge has already been spent
- Contract conversion significantly slower than anticipated due to delays in project application approvals at the BSR
- At the end of January, the government has responded by moving responsibility for the BSR from the Health and Safety Executive, to become a standalone body within the Ministry of Housing Communities and Local Government
- The regulator's 2026–2027 Strategic Plan focuses on reducing delays and speeding up cladding remediation. It aims to decide most non-complex applications within 12 weeks, while improving quality, transparency, and industry engagement, and ensuring building control approval no longer delays remediation
- Unique platform form which to increase market share in a c.£50bn* market
- Focused to become the market leader in cavity fire barrier remediation work



150 buildings across the UK remediated with the Injectaclad system

IFC accredited / Compliant with statutory regulations

Increased number of BSR applications being specified / approved



LONDON
STOCK
EXCHANGE


19 RNS / RNSR's
and 12 shorts
published



24 interviews
completed

Marketing
Manager employed

Drone tours,
graphic design,
marketing and
comms



7 trade shows
attended

Media Room for content creation & interviews



Active on:



Group posts - (20/04/25 - 19/04/26)

- 437 posts
- 160,137 impressions
- 16,378 Reactions
- 279 comments
- 63 reposts

- £6.6m fundraising post year
- Transformational acquisitions for the Group, significantly enhancing our ability to generate revenue at scale
- Strengthened balance sheet provides a solid platform for sustainable and profitable growth
- c.£55m current Group quoted pipeline
- c.£4m forward orders
- Clear strategy with a route to market in expanding growth sectors
- Strong market opportunity providing platform for growth and improved margins, targeting £50m revenue in the medium term



Δ Combined Market Opportunity

Aggregation of the following 4 market sizes:

Report: Allied Market Research LED Grow Lights Market Analysis 2030; (<https://www.alliedmarketresearch.com/led-grow-lights-market-A12416>): USD \$12.3 billion by 2030 converted at GBP £1 = USD \$1.35.

Report: Agricultural Sensors Market 2032; (<https://www.credenceresearch.com/report/agriculture-sensors-market>): USD \$4.8 billion by 2032 converted at GBP £1 = USD \$1.35

Report - Horizon Grand View Research 2030 (<https://www.grandviewresearch.com/horizon/outlook/electronic-contract-manufacturing-and-design-services-market/uk>): USD \$28.2 billion by 2030 converted at GBP £1 - USD \$1.35.

<https://www.gov.uk/government/publications/building-safety-programme-estimates-of-ews1-requirements...> programme-estimates-of-ews1-requirements-on-residential-buildings-in-england, over 40,000 buildings requiring an EWS1, multiplied by the average remediation cost to date of similarly sized buildings per management's calculations.

DISCLAIMER

IMPORTANT INFORMATION

The information contained in these slides and this presentation is being supplied to you by Light Science Technologies Holdings plc (the “Company”) solely for your information. For the purposes of this disclaimer references to the “Presentation” shall mean and include the slides that follow, any video recording or oral briefing in connection with the slides, any question-and-answer session(s) that follow(s) the oral presentation, hard or soft copies of this document and any materials distributed at, or in connection with the Presentation.

This Presentation may not be published, distributed, copied, reproduced, in whole or in part, or otherwise disseminated, directly or indirectly, to the press or any other person. Failure to comply with this restriction may, inter alia, constitute a violation of applicable securities laws.

The content of this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”). This Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities of the Company nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract, commitment or investment decision in relation to any such matter nor does it constitute a recommendation regarding the securities of the Company. Investors and prospective investors in securities of the Company are required to make their own independent investigation and appraisal of the business and financial condition of the Company and the nature of the securities.

This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

This Presentation is for distribution in the United Kingdom only to persons who are (1) authorised or exempt persons within the meaning of FSMA; or (2) persons who have professional experience in matters relating to investments falling within Article 19(5) and/or Article 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (3) "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) as amended, as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018; or (4) persons who are otherwise permitted by law to receive it (collectively referred to as “relevant persons”). The Presentation and any accompanying materials are directed only at relevant persons. Other persons should not act or rely on this Presentation or any of its contents.

The shares of the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “US Securities Act”), or under the applicable securities law or with any securities regulatory authority of any state or jurisdiction of the United States, and may not be offered or sold, resold, transferred or delivered, directly or indirectly, in the United States or to, or for the account or benefit of, US Persons (as defined in Regulation S under the US Securities Act), except pursuant to an exemption from, or a transaction not subject to, the registration requirements of the US Securities Act. Neither this Presentation nor any part or copy of it may be taken, transmitted or distributed, directly or indirectly, by any means (including electronic transmission) in or into: (a) the United States, its territories or possessions or to any US Person (“United States”); or (b) Canada, Australia, New Zealand, the Republic of South Africa or Japan, (“together with the United States, being a “Restricted Territory”); or (c) distributed to any individual outside a Restricted Territory who is a citizen, national or resident thereof, or to any corporation, partnership or other entity created or organised under the laws of those. Any such transmission or distribution could result in a violation of relevant securities laws of such jurisdictions.

This Presentation may include certain forward-looking statements, beliefs or opinions relating to the Company and its subsidiaries or proposed subsidiaries (the “Group”), including statements with respect to the Group’s business, financial condition and results of operations. These statements also relate to the future prospects, developments and business strategies of the Company and its Group. These statements, which contain words such as “anticipate”, “believe”, “intend”, “estimate”, “expect”, “forecast”, “could”, “may”, “plan”, “predict”, “project”, “will” or the negative of those variations and words of similar meaning are contained in all sections of the Presentation and reflect the Directors’ beliefs and expectations and involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. No representation is made that any of these statements or forecasts will come to pass or that any forecast results will be achieved. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance cannot be relied on as a guide to future performance of the Company or any member of the Group. Forward-looking statements speak only as at the date of this Presentation and the Company expressly disclaims any obligations or undertaking to release any update of, or revisions to, any forward-looking statements in this Presentation. No statement in this Presentation is intended to be a profit forecast. As a result, you are cautioned not to place any undue reliance on such forward-looking statements.

This Presentation speaks as of the date hereof. The contents of this Presentation have not been verified and no reliance may be placed for any purposes whatsoever on the information contained in this document or on its completeness, accuracy or fairness. Any reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. The Company, their advisers and each of their respective members, directors, officers and employees are under no obligation to update or keep current the information contained in this Presentation, to correct any inaccuracies which may become apparent, or to publicly announce the result of any revision to the statements made in this document except where they would be required to do so under applicable law, and any opinions expressed in the Presentation are subject to change without notice. None of the Company or any of its subsidiary undertakings or affiliates or directors, officers or any other person (including any of the advisers to the Company) accepts any responsibility whatsoever, nor makes any representation or warranty, express or implied, as to the fairness, accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever for any loss howsoever arising from any use of this Presentation or its contents otherwise arising in connection therewith is accepted by any such person in relation to such information. The Company accordingly disclaims all and any responsibility or liability (whether arising in tort, contract or otherwise) which it may otherwise have in respect of this Presentation or its contents. If the recipient is in any doubt about the contents of this Presentation and any accompanying materials or any action to be taken, the recipient should consult a person authorised for the purposes of FSMA or from another appropriately authorised advisor if they taking advice in a territory outside the United Kingdom. By attending or viewing the Presentation you agree to be bound by the foregoing limitations and warrant and undertake to the Company that: (i) you are a relevant person and you will observe the foregoing provisions, limitations and conditions; and (ii) you have read, agree to and will comply with the terms of this disclaimer

Questions | Thank you

